Celldex Therapeutics, Inc (CLDX) Dividend History

Company News

• Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025

  Celldex's barzolvolimab demonstrated rapid, robust, and durable improvements in angioedema symptoms over 52 weeks in a Phase 2 study for chronic spontaneous urticaria, with up to 77% of patients being angioedema-free at Week 52.

  GlobeNewswire Inc.
• Analyst Expectations For Celldex Therapeutics's Future - Benzinga

  Analysts have released a range of ratings for Celldex Therapeutics, with an average 12-month price target of $77.4. The company's financial performance shows challenges, with a decline in revenue and below-industry net margin, but strong return on equity and assets.

  Benzinga
• Wall Street Analysts Think Celldex (CLDX) Could Surge 87.27%: Read This Before Placing a Bet

  The mean of analysts' price targets for Celldex (CLDX) points to an 87.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

  Zacks Investment Research
• Street Calls of the Week: Pepsi may fizzle out

  Investing.com

  Featured Companies: KDP KO NKE PEP SPOT
• Why Celldex Therapeutics Blasted 13% Higher on Monday

  The biotech's CSU treatment advanced in the laboratory.

  The Motley Fool